F. Souami

Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.

M. Dimopoulos, D. Bae, P. Schwartz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2016, The New England journal of medicine.

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

K. Blackwell, J. Kim, S. Verma, 2016 .

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

G. Hortobagyi, D. Cameron, L. Hart, 2017, Breast Cancer Research and Treatment.

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

S. Verma, M. Campone, L. Hart, 2017, Breast Cancer Research and Treatment.

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2

M. Campone, L. Hart, H. Burris, 2017 .